FINEOS
21.10.2020 00:17:09 CEST | Business Wire | Press release
FINEOS Corporation (ASX:FCL ), the market-leading provider of group and individual core systems for life, accident and health insurance, today announced that it has executed a Heads of Agreement (HoA) with QInsure , a wholly owned subsidiary of the QSuper Group, one of Australia’s largest and most respected superannuation funds, which signals the intent to upgrade QInsure’s FINEOS Claims system to the FINEOS Claims SaaS edition on the FINEOS Platform, powered by AWS.
QInsure implemented and went live with FINEOS Claims in September 2019, which successfully delivered member-centric claims outcomes via improved, integrated and automated processes and workflow for claims covering life, Total and Permanent Disability (TPD) and Income Protection. Key highlights of the program included automatic payment calculations and the FINEOS Financial Services Council (FSC) Code of Practice business content that help case managers deliver on the insurance promise and meet regulatory obligations.
Speaking about the relationship, CEO of QInsure, Phil Fraser said, “Our partnership with FINEOS continues to grow and we are realising benefits from the FINEOS Claims system, including streamlined claims processes which enables our Claim Managers to focus on providing excellent outcomes to QSuper members. We are excited to continue our partnership with FINEOS to help support our organisation agility, digital customer experience and our service excellence.”
Mr Fraser added “While our partnership with FINEOS is relatively new, they have proven to be a reliable and valued partner. We will be working closely with FINEOS under this HoA to ensure APRA (the Australian Prudential Regulation Authority) is supportive of our approach.”
Michael Kelly , CEO, FINEOS concluded, “QInsure is a fantastic company to be in partnership with given their strong commitment to always doing the best by their members. We are excited about the next phase of our partnership with one of the most respected funds in Australia. The move to the FINEOS Platform is an exciting opportunity for FINEOS and our clients in the Australian and New Zealand region. Supporting this transition is a key strategic objective for FINEOS. Our North American clients have already adopted our SaaS based FINEOS Platform solutions over the past 3-4 years and we have been a ‘cloud only’ SaaS vendor in the US and Canada for over 3 years now.”
Last year FINEOS achieved record new sales of core solutions on the FINEOS Platform and we are seeing widespread interest in cloud solutions in Australia and New Zealand today. Covid-19 has accelerated Digital Transformation within the life, accident and health industry and carriers want to move to cloud computing in support of having flexible, modern business models which support working, buying and obtaining customer service that can be achieved from anywhere.
Over the past 6 years FINEOS has invested over €100m in R&D to develop FINEOS AdminSuite , an end-to-end SaaS core administration system for life, accident and health, including policy, billing and claims management. FINEOS listed on the ASX in 2019, and in August 2020 FINEOS acquired Limelight, a Silicon Valley SaaS provider of Quote, Underwrite and Rating software to the group and voluntary employee benefits industry in the US.
FINEOS enjoys established, trusted relationships with some of the largest and most respected carriers across the ANZ region. We pride ourselves on a very strong local team that has an enviable delivery and client support track record, and we are delighted to continue to work in partnership with QInsure.”
About FINEOS Corporation Limited
FINEOS is a leading provider of core systems for life, accident and health insurers globally with 6 of the largest life insurers in Australia as well as 7 of the 10 largest group life and health carriers in the US. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides clients full end to end core insurance administration and includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com
About QInsure
QInsure was established to exclusively provide Group Life Insurance policies for QSuper, so life insurance benefits can be provided to QSuper members as part of their superannuation membership.
QInsure, the first insurance company set up by a superannuation fund in Australia, was established on 29 July 2015 as a wholly owned subsidiary of QSuper Limited and commenced issuing life insurance policies from 1 July 2016. The company has ASFL and APRA licenses to operate as an insurance company, as well as an independent Board of Directors and Executive Leadership Team.
About QSuper
QSuper started with an Act of Parliament in 1912 creating the entity now known as the QSuper Group.
Over time, QSuper expanded to become the superannuation fund for all current and former Queensland public sector employees and their spouses and is now Queensland’s largest super fund and one of the largest in Australia. QSuper has grown its range of products and services, with its customer base is now numbering more than 585,000 with over $113 billion in funds under administration.
With the passing of legislation in 2016 that removed the restrictions on who is eligible to join the Fund, from 1 July 2017 QSuper was able to welcome more Australians to experience the QSuper feeling.
For more information, visit https://qsuper.qld.gov.au/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020006052/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom